Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 4;9(1):33. doi: 10.3390/biomedicines9010033

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effect of bortezomib and ixazomib on human multiple myeloma cell viability. Viability of (A) bortezomib- and (B) ixazomib-treated KMS-20, KMS-26, and KMS-28BM cells, as measured by the trypan blue dye assay. These cells were treated with the indicated concentrations of bortezomib for 3 days. The results are representative of five independent experiments. * p < 0.01 vs. controls (viability of KMS-20 cells was analyzed by the Shapiro-Wilk test and one-way analysis of variance (ANOVA) with Dunnett’s test. The viability of the KMS-26 and KMS-28BM cells was analyzed by the Shapiro-Wilk and Kruskal-Wallis tests, followed by the Steel test). (C) half-maximal inhibitory concentration (IC50) of bortezomib and ixazomib for KMS-20, KMS-26, and KMS-28BM cells.